Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Reducing oral mucositis in patients treated with CRT using avasopasem manganese

Paolo Bossi • 5 Jun 2022
ASCO 2022
Head and Neck Cancer Avasopasem manganese
ROMAN

Paolo Bossi, MD, University of Brescia, Brescia, Italy, discusses the results of a Phase III trial of avasopasem manganese for severe oral mucositis in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Paolo Bossi

The future role of immunotherapy in head and neck cancer
1:37
The future role of immunotherapy in head and neck cancer
Paolo Bossi • 27 Mar 2023
HPV status, artificial intelligence, and IO in head and neck cancer
2:09
HPV status, artificial intelligence, and IO in head and neck cancer
Paolo Bossi • 27 Mar 2023
The role of quality of life in the management of head and neck cancer
4:29
The role of quality of life in the management of head and neck cancer
Paolo Bossi • 27 Mar 2023
Resistance to immune checkpoint blockade in patients with cSCC
1:20
Resistance to immune checkpoint blockade in patients with cSCC
Paolo Bossi • 5 Jun 2022

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals